Royalty Report: Cancer, Diagnostic, Drugs – Collection: 2305

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Cancer
  • Diagnostic
  • Drugs
  • Disease
  • Biotechnology
  • Medical
  • Genome
  • Drug Discovery
  • Technical Know How
  • Diagnostic Substances
  • Test/Monitoring
  • Assay
  • Software
  • DNA
  • Medical Info

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2305

License Grant
Licensor is providing the Company with an exclusive worldwide license to Licensor’s existing and future human genome technologies that are useful for the purposes of development and commercialization of certain of the Company's services, including (i) testing, detection and/or analysis of cancer-predisposing genes; (ii) genetic assessment of risk of an individual to develop cancer; and (iii) testing and analysis for the purposes of cancer management.
License Property
The proprietary technologies include functional gene assay and microsatellite instability technology.  In addition, the Company currently uses conventional gene sequencing to detect gene mutations.  The Company intends to utilize protein truncation methods, Oncor’s proprietary Tri-Amp DNA amplification technology, various gel electrophoresis screening methods and automation to detect genetic mutations.
Field of Use
The Licensee was formed to develop genetic testing and information services for the early detection and management of cancer.  Also engaged in research and development programs and organizational efforts.  The rights granted apply to the healthcare industry.

IPSCIO Record ID: 27384

License Grant
The Licensor is providing the Company with an exclusive worldwide license to certain of the Licensor’s existing human genome technologies that are useful for purposes of development and commercialization of certain of the Company’s services, including (i) testing, detection and/or analysis of cancer-predisposing genes; (ii) genetic assessment of risk of an individual to develop cancer; and (iii) testing and analysis for the purposes of cancer management.
License Property
In addition, the Licensor is providing the Company with a non-exclusive worldwide license to certain of the Licensor’s existing human genome technologies, and any future improvements thereto, to be used by the Company in the provision of services direct to third parties other than those to whom services are provided pursuant to the exclusive license.
Field of Use
The rights granted apply for the purposes of cancer management in the Medical Field using human genome technologies.

IPSCIO Record ID: 385644

License Grant
Licensor of the Netherlands grants an exclusive, non-transferable license under the Patents in the Territory, in the Field of Use, with a right to grant a Sublicense
License Property
Licensor is a biotechnology company active in the field of plant biotechnology, genomics and phenomics and has proprietary expertise related to next generation sequencing technologies.

Licensor Technology shall mean the KeyPoint® Technology.

KeyPoint® Technology shall mean Licensors proprietary technology for high-throughput screening and identification of mutations in targeted gene sequences covered by the Patent.

Field of Use
The Field of Use shall mean the generation and analysis of sequence information from extracellular, free-flowing nucleic acids obtained from human urine, whole blood, plasma, or serum samples in connection with a diagnosis, prognosis, or monitoring of cancer or the screening of healthy individuals to assess the risk of cancer in such individuals. For clarity, free-flowing refers to nucleic acids that are outside of intact cells in the human urine, whole blood, plasma, or serum samples.

IPSCIO Record ID: 319183

License Grant
Licensor grants a non-exclusive license, without the right to grant sublicenses, under the Licensed Patent Rights and Licensed Technology to make, distribute, use and sell Licensed Products within the Field and in the Territory.
License Property
Licensor is the owner of or otherwise controls certain patents and technology related to its proprietary DNA-based PST® Genetic Risk Assessment Test that may be used for the identification of persons at risk for developing periodontis.

Licensed Product means any product that uses, incorporates, is comprised of, or contains a PST® Genetic Risk Assessment Test.

Licensed Technology means any Technology Controlled by Licensor at any time during the Term that is related to the PST® Genetic Risk Assessment Test and is necessary or useful for Oral DNA to exercise the license granted.

PST® Genetic Risk Assessment Test means Licensors proprietary genetic test covered by one or more Licensed Patent Rights that detects variations in certain Interleukin-I genes in order to identify an individuals predisposition for over-expression of inflammation and risk for periodontal disease.

Field of Use
The PST® Genetic Test provides a means of assessing an individual's genetic risk for periodontal disease, the most common cause of tooth loss.  PST(R) Genetic Test is the first and only genetic test that analyzes interleukin 1 (IL1) genes for variations that identify an individual's predisposition for over-expression of inflammation and risk for more severe periodontal disease. The PST(R) Genetic Test was developed following numerous clinical studies, and more than 40 peer-reviewed articles have been published on the test.

The Field means all activities associated with the Diagnosis of periodontal disease.

Licensee desires to obtain patents and technology to make, distribute, use and sell PST® Genetic Risk Assessment Tests for use in the Field.

IPSCIO Record ID: 7118

License Grant
The Sublicensor is the exclusive Licensee of the Patent Rights  relating to the Field under the 2006 Exclusive License Agreement and is willing to grant the Sublicensee a non-exclusive royalty-bearing SubLicense.
License Property
Patent Rights shall mean Patent Application PCT/lT 2005/000634 filed October 28, 2005 entitled Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof (published as WO 2006/046270), subject to the rights granted by Original Licensor to the Sublicensor pursuant to the Exclusive License Agreement.

Nucleophosmin (NPM1) Gene Mutation Detection in Acute Myeloid Leukemia (NPM1 exon 12)
Indications for Molecular Testing
• Acute Myeloid Leukemia
Testing Methodology
NPM1 mutation detection involves polymerase chain reaction (PCR) followed by capillary electrophoresis separation to detect the most common insertion mutations (4 to 11 nucleotides) in NPM1 exon 12. (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Interpretation of DNA analysis Nucleophosmin-1 (NPM1) gene codes for a nucleocytoplasmic shuttling protein that plays a key role in cellular processes including ribosome biogenesis, genomic stability, regulation of transcription, and modulation of tumor suppressor gene transcription. NPM1 is the most common genetic abnormality in AML.

Field of Use
The Field is Laboratory Services for testing nucleophosmin protein (NPM1) nucleic acid mutations, including the monitoring of minimal residual disease, in all human sample specimens. For avoidance of doubt, the Field strictly includes molecular testing.

IPSCIO Record ID: 299285

License Grant
University grants an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use and sell joint licensed products.
License Property
The University jointly owns and is a joint proprietor of certain intellectual property relating to the human BRCA-2 breast cancer gene.
Field of Use
The field of use means any and all applications and uses of the BRCA-2 breast cancer gene, including but not limited to all diagnostic and therapeutic applications.

IPSCIO Record ID: 211922

License Grant
This Agreement is to develop, manufacture, and commercialize innovative diagnostic systems integrating proprietary Licensor assays and technologies, and proprietary Licensee technologies and systems.

Pursuant to this agreement, The Belgian Licensor will have exclusive distribution rights in the territory.   If the R&D Collaboration results in development of a sample preparation cartridge for extraction of genomic DNA that does not incorporate proprietary Licensors technology and that is generically applicable for any procedure based on analysis of human genomic DNA, then Licensee agrees not to provide such cartridge for sale by another party to be licensed and approved for use in HLA apolipoprotein E, or CF gene (for cystic fibrosis) which are current market areas for Licensor; for a time period of (18) months.

License Property
The focus of this collaboration is the development of products integrating our proprietary technologies for sample preparation, rapid amplification and detection and Licensor's proprietary methods for genetic testing and viral genotyping.

Licensee has certain proprietary technology and experience relating to diagnostic assay reagents, protocols, and detection systems.

Products shall mean systems, subsystems, consumables, and software resulting from the R&D Collaboration and incorporating proprietary Licensee technology and proprietary Licensor technology, or systems, subsystems, and consumables incorporating proprietary Licensee technology that are specifically designed and produced according to Licensor approved Product Requirements and Specifications for use with proprietary Licensor technology and assay procedures.

Field of Use
The Field shall mean human diagnostics, as evidenced by regulatory labeling indicating approval for use in human diagnostics or for investigation of putative clinical utility by a diagnostics laboratory in a clinical research setting (e.g. For Investigational Use Only or For Research Use Only); food testing; and veterinary testing.

IPSCIO Record ID: 299283

License Grant
Licensor of Canada grants an exclusive license under Licensors patent rights to make, have made, use, and sell Licensed Products and to practice the Licensed methods throughout the world where Licensor may lawfully grant such a license.

Licensor also grants to the right to issue sublicenses.

License Property
Licensor has certain genetic research for the isolation, sequencing, and identification of cancer genes

Licensee has certain proprietary information and biological materials concerning the BRCA2 breast cancer gene.

Licensed technology also includes
—  the human BRCA2 gene(s);
—  any fragment(s) of material containing a DNA sequence from the BRCA2 gene(s);
—  any BRCA2 protein molecules;
—  nucleic acid molecules and monoclonal antibodies that bind to the BRCA2 gene(s) or its DNA sequence;
—  any mutations or altered form of the BRCA2 gene(s);
—  any animal or human homologues of the BRCA2 gene(s);
—  any other 'technologies' and/or products developed under this research collaboration required for diagnostic or therapeutic commercial applications of the BRCA2 gene.

Licensed technology further includes all uses of the BRCA2 gene(s) and its products, should they be isolated, characterized, developed or sequenced under this research collaboration, including such uses as diagnostic and therapeutic applications.

Field of Use
The field of use is for the commercial development, use and sale of any inventions that may result from the discovery of the BRCA2 breast cancer gene.

IPSCIO Record ID: 203310

License Grant
With this collaboration agreement, Licensor will develop and deliver to Licensee, a non-profit organization, The OmniBank II Library, install and support the Bioinformatics Software, and provide training to Licensees staff in the use of the OmniBank II Library and the production, genotyping and phenotyping of knockout mice.

Licensor will generate and deliver to Licensee two complete copies of a library consisting of three hundred fifty thousand (350,000) mouse embryonic stem cell clones with Selected Mutations, each identified by DNA sequence of its genomic integration site, the OmniBank II Library. Subject to the terms of this Agreement, Licensor will use Diligent Efforts to generate and deliver the OmniBank II Library in accordance with the schedule set forth in the Development Plan.

Licensor grants to Licensee the non-transferable, non-exclusive right under Licensors rights in the Cre-Lox Patents to use, breed and cross-breed Mutant Mice and Progeny that contain one or more lox sites in their genome (Lox Mice), at the internal research facilities of Licensee, solely for research purposes.

Licensor grants to Licensee a worldwide, non-exclusive right and license to use the Bioinformatics Software, under the copyrights and know-how Controlled by Licensor with respect thereto. Licensee shall have the right under the foregoing license to custom configure the Bioinformatics Software for its internal use.

License Property
Licensor has technology for and expertise in the generation of mouse embryonic stem cell clones containing gene trap mutations that can be used in the production of knockout mice.

The Bioinformatics Software means the software for the management and analysis of data relating to the OmniBank II Library and the production, genotyping and phenotypic analysis of knockout mice.

The library, constructed using Licensor's proprietary mouse gene knockout technology, will enable a researcher to develop a mouse that has a specific gene removed or “knocked-out.” The function of that gene can then be studied by comparing the knockout mouse to a normal mouse. Approximately 99 percent of human genes have a mouse counterpart, and research using this technology may lead to the development of drugs for a wide variety of human and animal diseases, including diabetes and obesity, infectious disease, cancer and heart disease. Institute researchers will have certain rights to utilize Lexicon’s patented gene targeting technologies. In addition, Licensor will equip the Institute with the bioinformatics software required for the management and analysis of data relating to the library.

Field of Use
This agreement is for the stem cell cloning industry and the identification of target genes and DNA.

IPSCIO Record ID: 273391

License Grant
Licensor hereby grants to Licensee, subject to all the terms and conditions of this Agreement, a worldwide, nonexclusive right and license (without the right to grant sublicenses) under the Patent Rights to (a) use, offer to sell, sell and practice Diagnostic Services in the Field; (b) make, have made, use, offer to sell, sell and import Licensed Reagents in the Field; and (c) make, have made, use, offer to sell, sell and import Kits in the Field. Notwithstanding the foregoing, Licensor hereby grants to Licensee the worldwide, non-exclusive right to convey to the end-user (purchaser) of FDA (U.S. Food and Drug Administration) Approved Kits manufactured by Licensee the right to perform Diagnostic Services solely in conjunction with the use of FDA Approved Kits manufactured by or on behalf of Licensee (without the right to grant sublicenses).
License Property
Patent Rights shall mean collectively the Gene Patent Rights and the Methodology Patent Rights.

Diagnostic Service(s) shall mean the performance of laboratory-based assays covered in whole or in part by a Valid Claim of the Patent Rights.

Gene Patent Rights shall mean the United States and foreign patents and patent applications relating to the APC (Adenomamus polyposis coli) gene and/or the p53 gene and licensed (with the right to grant sublicenses) to Licensor pursuant to the JHU (Johns Hopkins University) License Agreement together with patents arising therefrom and any extensions, registrations, confirmations, reissues, divisions, continuations or continuations-in-part, re-examinations or renewals thereof, including without limitation the patents and patent applications listed hereto (which may be updated from time to time to include such additional patents and patent application that may arise therefrom); provided, however, that Gene Patent Rights expressly excludes any claims of such patents and patent applications that fall outside of the Field, including, without limitation, claims to antibodies, to the treatment, prevention or remedying of a gene deficiency, to purified proteins, or to DNA (Deoxyribonucleic acid) sequences other than those sequences that correspond to the p53 gene and the APC (Adenomatous polyposis coli) gene; provided further that DNA sequences which are (i) immediately adjacent to the p53 or APC genes and (ii) necessary to the use of the p53 or APC genes, respectively, in the Field shall be considered within the Gene Patent Rights.

US Patent No.  5,352,775 – APC gene and nucleic acid probes derived therefrom
US Patent No.  5,527,676 – Detection of loss of the wild-type P53 gene and kits therefor

Methodology Patent Rights shall mean the United States and foreign patents and patent applications relating to methods of detecting mammalian nucleic acids isolated from stool specimens and reagents therefor and licensed (with the right to grant sublicenses) to Licensor pursuant to the JHU (Johns Hopkins University) License Agreement together with patents resulting therefrom and any extensions, registrations, confirmations, reissues, divisions, continuations or continuations-in-part, re-examinations or renewals thereof, including without limitation the patents and patent application listed hereto (which may be updated from time to time to include such additional patents and patent applications that may arise therefrom).

US Patent Application No. W093/20235 and 08/861,910 (detecting mammalian nucleic acids from stool)

Licensed Reagent shall mean any Reagent covered in whole or in part by a Valid Claim of the Patent Rights.

Kit shall mean a collection of one or more Reagents, including at least one Licensed Reagent, packaged in the form of a kit (including an FDA Approved kit).

Field of Use
Field shall mean (a) stool-based detection of any disease or condition (including pre-cancers, staging and monitoring of the foregoing, and therapeutic response) for research and development, Clinical Laboratory Improvement Amendments (CLIA) testing services (and their foreign equivalents), and FDA Approved Kits; and (b) a screening assay (regardless of other uses to which such assay is put) for colorectal cancer in any type of patient samples, excluding tests solely for staging and/or monitoring of colorectal cancer which do not obsolete or adversely impact such screening assay.

IPSCIO Record ID: 27967

License Grant
Licensor, is willing to grant to the sublicensee a worldwide, nonexclusive, royalty-bearing sublicense to use such patent rights for the development and commercialization of Diagnostic Services, Licensed Reagents and Kits.  Certain patent rights including but not limited to screening, diagnosis, prognosis and monitoring tests, for the purpose of detecting changes associated with colorectal cancer, were licensed under the agreement dated as of February 5, 1992.
License Property
Diagnostic Service(s) shall mean the performance of laboratory-based assays covered in whole or in part by a Valid Claim of the Patent Rights.

U.S. Patent No. 5,352,775 & U.S.  Patent Application No.  08/861,910

Field of Use
Field shall mean the determination, in stool or samples prepared from stool, of the presence of, absence of or variation(s) within a nucleic acid of interest, or differences between a nucleic acid of interest and a reference standard or sample, including but not limited to screening, diagnosis, prognosis and monitoring tests, for the purpose of detecting changes associated with colorectal cancer.

IPSCIO Record ID: 383582

License Grant
In the original agreement, Licensor granted
— For the Layton and Stanford Patent Rights a nonexclusive, non-transferrable, limited sub-licensable, world-wide license under the Layton Patent Rights and the Stanford Patent Rights to practice and use the subject matter within the Layton Patent Rights and the Stanford Patent Rights in the Licensee Database Field of Use, Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use.
— For the Montefiore Patent Rights, a non-transferrable, limited sub-licensable, world-wide license under the Montefiore Patent Rights to practice and use the subject matter within the Montefiore Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use.
— For the Cancer Marker Patent Rights, Licensor grants a non-transferrable, limited sub-licensable, world-wide license under the Cancer Marker Patent Rights to practice and use the subject matter within the Cancer Marker Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use, only with respect to cancer.
— For the Database Patent Rights and Seilhamer/Scott Patent Rights, Licensor grants a nonexclusive, non-transferable, non-sublicensable , world-wide license under the Database Patent Rights and Seilhamer/Scott Patent Rights to practice and use the subject matter within the Database Patent Rights and the Seilhamer/Scott Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use, and the Personalized Research Field of Use.
— For the Sublicenses, Licensee shall have the right to grant sublicenses to third parties under such Patent Rights on a Product-by-Product basis to make, use, import, sell, and offer for sale Products developed by Licensee or its Affiliates.
— For the Co-Exclusive Licenses in the Homebrew and Diagnostic Fields of Use, Co-Exclusive shall mean that each Party has the right to exercise all of the rights under the Patent Rights in question in the field of use for which the parties have co-exclusive rights, without obligation to the other except to the extent provided in this Agreement, and neither Party alone has the right to grant sublicenses to third parties under such Patent Rights without express written consent of the other Party.
License Property
Cancer Marker Patent Rights shall mean all Valid Claims listed in any of the following patents and patent applications, to the extent that they are owned by Licensor with the right to license under this Agreement, and to the extent that they claim the composition of matter or use of any nucleic acids or proteins as markers or diagnostics for cancer.

The patents include
— Processes for Genetic Manipulations Using Promoters;
— Method for Detecting Pathological Conditions;
— Comparative Gene Transcript Analysis; and,
— Methods for Fabricating Micro Arrays of Biological Samples.

Field of Use
Licensee licenses various classes of patents from Licensor pertaining to the manipulation of genes, the detection of pathological conditions, comparative gene analysis, methods for fabricating tests of biological samples and the use of proteins as markers for cancers.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.